姜黄素对脊索瘤细胞增殖、侵袭与迁移的影响及其机制  

Effects and mechanism of curcumin on proliferation,invasion and migration of chordoma cells

作　　者：邹康 王克 刘志峰 江宁宁[1] 梁潇潇 郭姗姗 Zou Kang;Wang Ke;Liu Zhifeng;Jiang Ningning;Liang Xiaoxiao;Guo Shanshan(Department of Osteopathy and Bone Oncology,Yantaishan Hospital,Yantai 264043,China;Department of Pathology,Yantaishan Hospital,Yantai 264043,China;Department of Health Examination,Yantaishan Hospital,Yantai 264043,China;Department of General Medicine,Rocket Force Specialty Medical Center,Beijing 100088,China)

机构地区：[1]烟台市烟台山医院骨病与骨肿瘤科,烟台264043 [2]烟台市烟台山医院病理科,烟台264043 [3]烟台市烟台山医院健康体检科,烟台264043 [4]火箭军特色医学中心全科医学科,北京100088

出　　处：《中华实验外科杂志》2025年第1期91-94,共4页Chinese Journal of Experimental Surgery

基　　金：2022年度军队后勤自主科研项目(20221102)。

摘　　要：目的探究姜黄素调控Notch信号通路对脊索瘤细胞生物学行为的影响。方法2023年1月至2023年10月于火箭军特色医学中心完成研究,体外培养人脊索瘤细胞株U-CH1,采用随机数字表法分为正常组、姜黄素处理组(5、10、20μmol/L姜黄素)和姜黄素+Notch信号通路激活剂(Jagged1/FC)组,采用细胞计数试剂盒(CCK-8)检测细胞增殖,流式细胞术检测细胞凋亡,Transwell小室检测细胞侵袭和迁移能力,蛋白印迹法检测半胱氨酸蛋白酶(Caspase-3、Caspase-9)上皮型钙黏蛋白(E-cadherin)、神经型钙黏蛋白(N-cadherin)、Notch1、Notch配体蛋白(Jagged1)和发状分裂相关增强子(Hes1)蛋白表达。采用单因素方差分析进行组间比较,两组间比较用独立样本t检验。结果10、20μmol/L姜黄素处理组48 h和72 h细胞活性均低于正常组(0.68±0.13、0.56±0.09比0.82±0.10,t=2.064、3.833,P<0.05;1.04±0.16、0.91±0.10比1.29±0.14,t=3.231、4.911,P<0.05)。10、20μmol/L姜黄素处理组细胞侵袭率、迁移率低于正常组[(8.95±6.78)%、(29.14±7.62)%比(63.28±9.75)%,t=5.192、7.285,P<0.05;(35.26±6.26)%、(23.95±5.81)%比(65.29±8.42)%,t=6.491、8.936,P<0.05],N-cadherin表达低于正常组(0.32±0.05、0.13±0.03比0.72±0.13,t=6.369、11.634,P<0.05),E-cadherin表达高于正常组(0.81±0.17、1.24±0.21比0.29±0.07,t=5.923、8.737,P<0.05)。Notch1、Jagged1和Hes1蛋白表达低于正常组(0.57±0.11、0.23±0.07比1.18±0.19,t=7.535、11.735,P<0.05;0.20±0.07、0.11±0.02比1.01±0.17,t=13.083、14.536,P<0.05;0.26±0.05、0.10±0.03比0.68±0.15,t=7.334、10.127,P<0.05)。姜黄素+Jagged1/FC组48 h和72 h细胞活性高于20μmol/L姜黄素处理组(0.75±0.14、1.16±0.15比0.56±0.09、0.91±0.10,t=2.801、3.231,P<0.05);细胞侵袭率、迁移率高于20μmol/L姜黄素处理组[(44.62±8.15)%比(29.14±7.62)%,t=6.080,P<0.05;(40.57±7.03)%比(23.95±5.81)%,t=6.340,P<0.05];N-cadherin表达高于20μmol/L姜黄素处理组(0.70±0.15比0.13±0.03,t=10.533,P<0.05),E-cadhObjective To explore the effects of curcumin on biological behaviors of chordoma cells by regulating Notch signaling pathway.Methods The research was completed in Yantaishan Hospital,Yantai,between January and October 2023.Human chordosoma cell lines U-CH1 were cultured in vitro and divided into normal group,curcumin treatment group(5,10,20μmol/L)and curcumin+Notch signaling pathway activator(Jagged1/FC)group by a random number table method.Cells proliferation was detected by cell counting kit(CCK-8),apoptosis was detected by flow cytometry,cells invasion and migration were detected by Transwell chamber assay,expression levels of cysteine proteases(Caspase-3,Caspase-9),epithelial cadherin(E-cadherin),neural cadherin(N-cadherin),Notch1,Notch ligand protein(Jagged1)and hairy and enhancer of split 1(Hes1)proteins were detected by Western blotting.Inter-group comparison was performed by one-way analysis of variance,and pairwise comparison was performed by independent-samples t test.Results The cell viability at 48 h and 72 h in the 10μmol/L and 20μmol/L curcumin treatment groups was significantly reduced(0.68±0.13,0.56±0.09 vs.0.82±0.10,t=2.064,3.833,P<0.05;1.04±0.16,0.91±0.10 vs.1.29±0.14,t=3.231,4.911,P<0.05).The invasion and migration rates in the 10μmol/L and 20μmol/L curcumin treatment groups were lower than those in the normal group[(38.95±6.78)%,(29.14±7.62)%vs.(63.28±9.75)%,t=5.192,7.285,P<0.05;(35.26±6.26)%,(23.95±5.81)%vs.(65.29±8.42)%,t=6.491,8.936,P<0.05].N-cadherin expression was lower in the 10μmol/L and 20μmol/L curcumin treatment groups than that in the normal group(0.32±0.05,0.13±0.03 vs.0.72±0.13,t=6.369,11.634,P<0.05),while E-cadherin expression was higher than that in the normal group(0.81±0.17,1.24±0.21 vs.0.29±0.07,t=5.923,8.737,P<0.05).The protein expression levels of Notch1,Jagged1,and Hes1 in the 10μmol/L and 20μmol/L curcumin treatment groups were lower than those in the normal group(0.57±0.11,0.23±0.07 vs.1.18±0.19,t=7.535,11.735,P<0.05;0.20±0.07,0.11±0.02 vs

关 键 词：脊索瘤细胞 姜黄素 凋亡 迁移 侵袭 NOTCH信号通路 

分 类 号：R285[医药卫生—中药学]